Taysha Gene Therapies Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean Nolan and Kamran Alam, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Taysha Gene Therapies, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Sean Nolan | Chief Executive Officer and Director(Principal Executive Officer) | February 26, 2025 |
| Sean Nolan | ||
| /s/ Kamran Alam | Chief Financial Officer(Principal Financial Officer and PrincipalAccounting Officer) | February 26, 2025 |
| Kamran Alam | ||
| /s/ Phillip B. Donenberg | Director | February 26, 2025 |
| Phillip B. Donenberg | ||
| /s/ Sean Stalfort | Director | February 26, 2025 |
| Sean Stalfort | ||
| /s/ Sukumar Nagendran, M.D. | Director | February 26, 2025 |
| Sukumar Nagendran, M.D. | ||
| /s/ Alison Long, M.D., Ph.D. | Director | February 26, 2025 |
| Alison Long, M.D., Ph.D. | ||
| /s/ Laura Sepp-Lorenzino, Ph.D. | Director | February 26, 2025 |
| Laura Sepp-Lorenzino, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.